PCM
TCRR

Prelude Capital Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Prelude Capital Management’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-16,715
Closed -$30K – 1772
2022
Q3 		$30K Sell
16,715
-19,785
-54% -$57.4K ﹤0.01% 1254
2022
Q2 		$106K Sell
36,500
-17,200
-32% -$42.4K ﹤0.01% 1409
2022
Q1 		$148K Buy
53,700
+17,400
+48% +$54.7K ﹤0.01% 1339
2021
Q4 		$169K Buy
+36,300
New +$227K ﹤0.01% 1609

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Prelude Capital Management's TCRR Position: Q4 2022 in Review

Prelude Capital Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2022, closing a stake of 16,715 shares — an estimated $30K sold.

Prelude Capital Management first reported a position in TCRR in Q4 2021 and held it in 4 quarters. The position peaked at $169K in Q4 2021. 63 funds tracked by Wall St. Rank hold TCRR as of Q4 2022.

  • Prelude Capital Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Prelude Capital Management sold 16,715 TCR2 Therapeutics Inc. Common Stock shares in Q4 2022, an estimated $30K.
  • Prelude Capital Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2021 and held it in 4 quarters.
  • Prelude Capital Management's TCR2 Therapeutics Inc. Common Stock position peaked at $169K in Q4 2021.
  • 63 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2022.

Based on Prelude Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.